published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsSolaymani-Dodaran, 2021 1.22 [0.66; 2.26] 1.22[0.66; 2.26]Solaymani-Dodaran, 202110%373NAnot evaluable clinical improvement (time to event analysis only)detailed resultsSolaymani-Dodaran, 2021 0.94 [0.75; 1.17] 0.94[0.75; 1.17]Solaymani-Dodaran, 202110%380NAnot evaluable mechanical ventilationdetailed resultsSolaymani-Dodaran, 2021 1.62 [0.85; 3.08] 1.62[0.85; 3.08]Solaymani-Dodaran, 202110%373NAnot evaluable ICU admissiondetailed resultsSolaymani-Dodaran, 2021 1.23 [0.70; 2.18] 1.23[0.70; 2.18]Solaymani-Dodaran, 202110%373NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-01 18:53 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290